GlassScriptPhysician profile
Joseph T Martins
NPI 1407852700
$20,793.90
in general payments reported to CMS, 2019-2025
57 companies · $896 in 2025
The $896 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,341 · 2020: $3,086 · 2021: $1,203 · 2022: $5,268 · 2023: $6,722 · 2024: $1,277 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,550 · Food and Beverage: $3,607 · Travel and Lodging: $538 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,550.00 |
| Food and Beverage | $3,607.46 |
| Travel and Lodging | $538.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $9,801.78 | 2019-2025 | Opdivo |
| Novocure INC. | $5,208.73 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $386.92 | 2019-2025 | Imjudo, Imfinzi, Calquence |
| Abbvie INC. | $379.57 | 2024-2025 | |
| Pfizer INC. | $326.51 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $315.17 | 2021-2025 | |
| Janssen Biotech, INC. | $308.79 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Celgene Corporation | $284.53 | 2019-2023 | Pomalyst, Reblozyl |
| Amgen INC. | $269.29 | 2020-2023 | Xgeva, Nplate, Lumakras |
| Regeneron Healthcare Solutions, INC. | $248.10 | 2019-2025 | Libtayo |
| Glaxosmithkline, LLC. | $220.61 | 2021-2024 | Zejula, Jemperli, Ojjaara |
| Genzyme Corporation | $212.16 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.78 | 2020-2023 | Ninlaro |
| Array Biopharma INC | $165.63 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Pharmacyclics LLC, An Abbvie Company | $157.42 | 2020-2023 | Epkinly, Imbruvica |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $148.79 | 2019-2025 | Vyloy, Xtandi, Padcev |
| Genentech USA, INC. | $147.77 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Incyte Corporation | $130.91 | 2019-2025 | Monjuvi, Jakafi |
| Tempus Ai, INC | $128.45 | 2024-2025 | Xt Cdx |
| Exelixis INC. | $124.82 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $123.71 | 2019-2024 | Keytruda, Lynparza |
| Karyopharm Therapeutics INC. | $110.55 | 2023 | Xpovio |
| Rigel Pharmaceuticals, INC. | $102.48 | 2021-2024 | Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $101.75 | 2024-2025 | |
| Gilead Sciences, INC. | $81.01 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $79.19 | 2023 | Myrisk |
| Emd Serono, INC. | $64.24 | 2022-2024 | |
| Immunocore Limited | $59.73 | 2023 | Kimmtrak |
| Eisai INC. | $55.24 | 2021-2024 | |
| Taiho Oncology, INC. | $51.13 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $48.96 | 2023-2024 | Ultomiris |
| Lilly USA, LLC | $47.57 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Blueprint Medicines Corporation | $46.91 | 2022-2023 | Ayvakit |
| Kite Pharma, INC. | $44.30 | 2022-2024 | Yescarta |
| Seagen INC. | $41.22 | 2020-2023 | Padcev |
| Sobi, INC | $39.83 | 2023 | |
| Morphosys, US INC. | $36.04 | 2022-2023 | Monjuvi |
| Galvanize Therapeutics, INC | $35.77 | 2025 | Aliya System |
| Dendreon Pharmaceuticals LLC | $35.67 | 2019 | |
| Myovant Sciences INC. | $34.81 | 2022 | |
| Sumitomo Pharma America, INC. | $34.23 | 2023 | Orgovyx |
| Adc Therapeutics America, INC. | $33.33 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.32 | 2023 | |
| Tesaro, INC. | $26.71 | 2019 | |
| Springworks Therapeutics, INC. | $23.76 | 2025 | Ogsiveo |
| Stemline Therapeutics INC. | $23.24 | 2024 | Orserdu |
| Eagle Pharmaceuticals, INC. | $22.72 | 2020 | |
| Sun Pharmaceutical Industries INC. | $22.72 | 2023 | Odomzo, Yonsa |
| Tersera Therapeutics LLC | $22.28 | 2022 | |
| Apellis Pharmaceuticals, INC. | $22.07 | 2022 | |
| Mirati Therapeutics, INC. | $21.91 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $18.48 | 2025 | Monoferric |
| Acrotech Biopharma INC. | $17.86 | 2023 | Beleodaq |
| Daiichi Sankyo INC. | $17.35 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.79 | 2019 | |
| Epizyme, INC. | $16.24 | 2022 | |
| Kyowa Kirin, INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Martins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.